Previous studies have shown that PAQR3 is involved in the resistance of NSCLC to the EGFR inhibitor erlotinib3, and in our study, it was found that the expression level of PAQR3 is related to the sensitivity of multiple drugs. This evidence concerns the gene EGFR and non-small cell lung carcinoma.